Liz King Email

SVP - Global Product Leader, Inhaled Therapeutics . Vectura Group plc.

Current Roles

Employees:
480
Revenue:
$96.5M
About
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. \n\nVectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.\n\nFor further information, please visit Vectura's website at www.vectura.com
Vectura Group plc. Address
One Prospect West
Chippenham, null
UK
Vectura Group plc. Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.